Diagnostic and Prognostic Biomarkers in Parkinson Disease (PROBE)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2008 by The Parkinson Study Group.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
The Parkinson Study Group
ClinicalTrials.gov Identifier:
NCT00653783
First received: April 2, 2008
Last updated: December 30, 2008
Last verified: December 2008

April 2, 2008
December 30, 2008
August 2007
July 2008   (final data collection date for primary outcome measure)
α-synuclein, transcriptomic profiles and olfactory function [ Time Frame: Three years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00653783 on ClinicalTrials.gov Archive Site
  • Unified Parkinson Disease Rating Scale (UPDRS) [ Time Frame: Three Years ] [ Designated as safety issue: No ]
  • University of Pennsylvania Smell Identification Test (UPSIT) [ Time Frame: Three Years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Diagnostic and Prognostic Biomarkers in Parkinson Disease
Blood Alpha-Synuclein, Gene Expression, and Smell Testing as Diagnostic and Prognostic Biomarkers in Parkinson's Disease

The overall goal of PROBE is to evaluate the feasibility and potential utility of three markers (alpha-synuclein, transcriptomic profiles and olfactory function) to determine the risk or prognosis of PD.

PROBE will test three biomarkers in PD subjects and controls to determine their feasibility and potential utility as markers of risk and prognosis for PD. This is a case control study, in which PD subjects will be compared to neurologically healthy controls and disease controls (MSA and PSP). The blood biomarker samples will be drawn once to evaluate blood alpha-synuclein levels as well as collection of lymphocyte mass for array analysis. Olfaction will be measured using the UPSIT for all subjects. The UPSIT will be conducted as part of PostCEPT for PD subjects and will only be repeated in this study for PD subjects in not done within 6 months. Control subjects may also choose to submit a blood specimen for processing and storage at the Coriell Institute for Medical Research, a research resource supported by the NINDS Human Genetics Resource Center.

Follow-up of the PD population over a 3-year period will allow us to evaluate the prognosis for important motor aspects of PD that will occur frequently in this cohort. These complications of PD include motor complications, postural instability, and non-motor impairment such as cognitive decline.

Healthy and disease control subjects may give permission at the Baseline visit to be contacted and followed in the previously established PSG FOUND study using mail and telephone contact to assess clinical status. Participation in the FOUND study provides another mechanism to maintain contact with subjects and collect supplemental data beyond that collected at the PROBE Baseline visit.

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Whole Blood, serum

Non-Probability Sample

primary care clinic, spouses, PD patients from another trial

  • Parkinson Disease
  • Multiple System Atrophy
  • Progressive Supranuclear Palsy
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
200
Not Provided
July 2008   (final data collection date for primary outcome measure)

Parkinson Disease Inclusion Criteria:

  • Subject is participating in PostCEPT and meets UK brain bank criteria for PD
  • Willing and able to provide informed consent

Healthy Control Inclusion Criteria:

  • Spouse or non blood relative of the PD subject
  • No known current diagnosis or history of a neurological disease
  • MMSE score >27
  • Age >45
  • Willing and able to provide informed consent

Parkinsonism/Disease Control Inclusion Criteria (MSA and PSP)

  • A diagnosis of Probable MSA based on Consensus Criteria OR Probable PSP based on NINDS-PSP Criteria
  • Willing and able to provide informed consent

Exclusion Criteria for All Groups:

  • Current use (within 7 days prior to Baseline Visit) of anticoagulants (e.g., warfarin or heparin)
  • Known bleeding disorder (acquired or inherited)
  • Known blood disorder (e.g. leukemia) or a history of anemia with a documented hematocrit <30
  • Known pregnancy
  • History of nasal trauma, sinusitis, or other nasal pathology that would interfere with smell testing
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00653783
U01NS050095-02_PROBE, DOD Grant # W81XWH-07-1-0007, NINDS Grant 5 U01 NS050095-02
No
Bernard Ravina, MD, MSCE, Principal Investigator, University of Rochester, Clinical Trials Coordination Center
The Parkinson Study Group
Department of Defense
Principal Investigator: Bernard Ravina, MD University of Rochester
The Parkinson Study Group
December 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP